AU2020360413A1 - Methods of treating conditions related to the S1P1 receptor - Google Patents

Methods of treating conditions related to the S1P1 receptor Download PDF

Info

Publication number
AU2020360413A1
AU2020360413A1 AU2020360413A AU2020360413A AU2020360413A1 AU 2020360413 A1 AU2020360413 A1 AU 2020360413A1 AU 2020360413 A AU2020360413 A AU 2020360413A AU 2020360413 A AU2020360413 A AU 2020360413A AU 2020360413 A1 AU2020360413 A1 AU 2020360413A1
Authority
AU
Australia
Prior art keywords
compound
individual
disease
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020360413A
Other languages
English (en)
Other versions
AU2020360413A8 (en
Inventor
Lisette Marie ACEVEDO
Thai Curtis NGUYEN-CLEARY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of AU2020360413A1 publication Critical patent/AU2020360413A1/en
Publication of AU2020360413A8 publication Critical patent/AU2020360413A8/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020360413A 2019-10-01 2020-09-30 Methods of treating conditions related to the S1P1 receptor Pending AU2020360413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
AU2020360413A1 true AU2020360413A1 (en) 2022-04-14
AU2020360413A8 AU2020360413A8 (en) 2022-04-21

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020360413A Pending AU2020360413A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the S1P1 receptor

Country Status (12)

Country Link
US (1) US20220347158A1 (https=)
EP (1) EP4037678A4 (https=)
JP (1) JP2022550458A (https=)
KR (1) KR20220074913A (https=)
CN (2) CN115038438A (https=)
AU (1) AU2020360413A1 (https=)
BR (1) BR112022005999A2 (https=)
CA (1) CA3156182A1 (https=)
IL (1) IL291654A (https=)
MX (1) MX2022003982A (https=)
TW (1) TW202114656A (https=)
WO (1) WO2021067506A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240134360A (ko) 2022-01-13 2024-09-09 아레나 파마슈티칼스, 인크. 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
JP5856980B2 (ja) * 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) * 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es) * 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.

Also Published As

Publication number Publication date
AU2020360413A8 (en) 2022-04-21
WO2021067506A1 (en) 2021-04-08
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12
US20220347158A1 (en) 2022-11-03
TW202114656A (zh) 2021-04-16
CN119280227A (zh) 2025-01-10
KR20220074913A (ko) 2022-06-03
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
EP4037678A4 (en) 2023-11-29
CA3156182A1 (en) 2021-04-08
JP2022550458A (ja) 2022-12-01
MX2022003982A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
KR20140138694A (ko) 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
KR20160148050A (ko) 라퀴니모드를 이용한 크론병의 치료
JP2025024035A (ja) S1p1受容体に関連する状態を治療する方法
Chang et al. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report
WO2022099150A1 (en) Methods of treating conditions related to the s1p1 receptor
AU2020360413A1 (en) Methods of treating conditions related to the S1P1 receptor
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
TWI855501B (zh) 治療方法
US20240277662A1 (en) Administration of a Compound to Individuals with Hepatic Impairment
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
HK40109901A (zh) 与激素治疗组合的用於治疗s1p1受体相关病症的伊曲莫德
HK40116488A (zh) 治疗与s1p1受体有关的病况的方法
WO2026043678A1 (en) Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy
AU2023203085A1 (en) Methods of treating conditions related to the S1P1 receptor
WO2021234430A1 (en) Modified release dosage form comprising vildagliptin and process for manufacturing the same

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 15 , PAGE(S) 2215 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ARENA PHARMACEUTICALS, INC., APPLICATION NO. 2020360413, UNDER INID (54) CORRECT THE TITLE TO READ METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR